Research Update

Deltex Medical Group PLC
24 September 2004



                            Deltex Medical Group plc

                   Further confirmation of CardioQ's benefits


 30% reduction in hospital stay and the potential to save NHS £1 billion a year



24 September 2004:  Deltex Medical Group plc ('Deltex' or the 'Company'), the
haemodynamic monitoring company, today announces the results of a randomised
controlled clinical trial conducted at Worthing Hospital investigating the
impact of haemodynamic optimisation, using the Company's CardioQ system, on
patients undergoing bowel surgery.



The clinical trial results, presented by Worthing Hospital's consultant
anaesthetist Dr Howard Wakeling at the annual Association of Anaesthetists of
Great Britain and Ireland conference in Cardiff, showed that use of the CardioQ
system significantly reduced post-surgical complications, improved patient
outcomes and saved approximately £25,000 across the 64 patients who were treated
with the device.  The trial demonstrated that giving fluid to patients based on
blood flow measurements using the CardioQ system significantly improved patient
outcomes compared to the current best (though far from routine) practice of
patient management based on blood pressure measurements.



This result complements recent studies completed 'in the field' by anaesthetists
and surgeons at the Medway Maritime Hospital NHS Trust in Gillingham, Kent.
Working with senior hospital managers, consultant anaesthetist Dr Graeme Sanders
and team analysed the impact of routinely using the CardioQ system across a
range of moderate and major surgical procedures.  Further data has now been
collected and its analysis completed, which demonstrates that across the whole
audit the average length of a hospital stay was reduced by 30%, compared to the
20% announced previously.



Medway Maritime Hospital NHS Trust Chief Executive, Andy Horne, commented:

'We have used the CardioQ in around 200 operations in the last four months and
have had very good results. It has improved quality of care for patients as they
are healthier post-theatre, need less post-operative care and get home quicker.
In addition to improving patient outcomes it improves efficiency and saves the
Trust a considerable amount of money.  We are able to treat more patients
because they stay in hospital for shorter times. It is a win, win situation.
CardioQ could potentially save the Medway Maritime Hospital Trust at least £1
million a year, which is equivalent to the running costs of one ward for a year.
'



Deltex Chief Executive, Andy Hill, commented:

'The clinical trials undertaken at Worthing further highlight the clinical and
economic benefits of haemodynamic optimisation in patients undergoing surgery.
If every major surgery hospital in the UK adopted hameodynamic optimisation as
standard during/post operative care, we estimate that it could potentially save
the NHS around £1billion a year.  The benefits of the CardioQ system have been
demonstrated scientifically and in the real world of the hospital - we believe
it should be incorporated as a standard of care as a matter of urgency.'


For further information, please contact:-

Deltex Medical Group plc
Nigel Keen, Chairman                                01243 774 837
Andy Hill, Chief Executive
Ewan Phillips, Finance Director

Financial Dynamics
Lucy Briggs                                         020 7269 7223
David Yates                                         020 7269 7156



Notes for Editors



Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolemia, which leads to
insufficient oxygen being delivered to the organs.  This causes medical
complications including peripheral and major organ failure which can lead to
death.  Hypovolemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself.  Using fluids and drugs, guided by the CardioQ, to optimise the amount
of circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.



The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.



There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-



  • validated the results of the Monitor against known standards for measuring
    cardiac output, demonstrating that the technology works



  • proved that the CardioQ works in a wide range of surgical procedures



  • demonstrated that the Company's technology provides significant health and
    economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.




                      This information is provided by RNS
            The company news service from the London Stock Exchange